That's something most shareholders can agree on. It will bring growth beyond the mid teens guided by management. I was initially optimistic about it many years ago but I have tampered my hopes down after reading about many failed trial in the cardiovascular space. I'm sure the SP would take a hit if it failed but if successful the uplift in SP would be a lot more than the hit imo.
$300 by calendar year end, page-14
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.33 |
Change
3.280(1.06%) |
Mkt cap ! $150.4B | |||
| Open | High | Low | Value | Volume |
| $310.00 | $312.47 | $310.00 | $172.6M | 554.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 130 | $311.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.50 | 210 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |